Strongly supporting this, the lung cancer–derived RBM10 mutant, RBM10-I316F, fails to bind to uL18 or uL5, to suppress c-Myc activity, and thus to inhibit lung cancer growth. Here, RPL5 is linked to lung carcinoma.